Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcin Okrój

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|March 15, 2021
Editorial: Complement and ImmunotherapeuticsMarcin Okrój, Elena Volokhina
Journal of Reproductive Immunology|March 11, 2022
Controversies around the statistical presentation of data on mRNA-COVID 19 vaccine safety in pregnant womenKrzysztof Bartoszek, Marcin Okrój
Pediatric Nephrology (Berlin, Germany)|February 19, 2021
Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndromeAlan Majeranowski, Marcin Okrój
Frontiers in Immunology|January 29, 2019
Complement Activation as a Helping Hand for Inflammophilic Pathogens and CancerMarcin Okrój, Jan Potempa
Acta Biochimica Polonica|July 2, 2003
Novel properties of antimicrobial peptidesWojciech Kamysz, Marcin Okrój, Jerzy Łukasiak
Autoimmunity Reviews|December 9, 2022
Will a hyperactive classical complement pathway exacerbate autoimmune diseases?Marcin Okrój, Santiago Rodriguez de Córdoba
Acta Biochimica Polonica|August 31, 2021
A tale of the monoclonal anti-CD20 antibodies, in tribute to prof. Wacław Szybalski (1921-2020)Grzegorz Stasiłojć, Marcin Okrój, Jacek Bigda
British Journal of Haematology|February 8, 2018
Parameters critical for the effector mechanism of anti-CD20 antibodies revisitedGrzegorz Stasiłojć, Anna Felberg, Marcin Okrój
Frontiers in Immunology|July 28, 2023
Editorial: Expert opinions and perspectives in complement: 2022Marcin Okrój, Nicolas S Merle, Jinhua Lu
Frontiers in Immunology|March 30, 2026
Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantificationAlan Majeranowski, Grzegorz Stasiłojć, Nadia Panasiuk, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|March 15, 2021
Editorial: Complement and ImmunotherapeuticsMarcin Okrój, Elena Volokhina
Journal of Reproductive Immunology|March 11, 2022
Controversies around the statistical presentation of data on mRNA-COVID 19 vaccine safety in pregnant womenKrzysztof Bartoszek, Marcin Okrój
Pediatric Nephrology (Berlin, Germany)|February 19, 2021
Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndromeAlan Majeranowski, Marcin Okrój
Frontiers in Immunology|January 29, 2019
Complement Activation as a Helping Hand for Inflammophilic Pathogens and CancerMarcin Okrój, Jan Potempa
Acta Biochimica Polonica|July 2, 2003
Novel properties of antimicrobial peptidesWojciech Kamysz, Marcin Okrój, Jerzy Łukasiak
Autoimmunity Reviews|December 9, 2022
Will a hyperactive classical complement pathway exacerbate autoimmune diseases?Marcin Okrój, Santiago Rodriguez de Córdoba
Acta Biochimica Polonica|August 31, 2021
A tale of the monoclonal anti-CD20 antibodies, in tribute to prof. Wacław Szybalski (1921-2020)Grzegorz Stasiłojć, Marcin Okrój, Jacek Bigda
British Journal of Haematology|February 8, 2018
Parameters critical for the effector mechanism of anti-CD20 antibodies revisitedGrzegorz Stasiłojć, Anna Felberg, Marcin Okrój
Frontiers in Immunology|July 28, 2023
Editorial: Expert opinions and perspectives in complement: 2022Marcin Okrój, Nicolas S Merle, Jinhua Lu
Frontiers in Immunology|March 30, 2026
Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantificationAlan Majeranowski, Grzegorz Stasiłojć, Nadia Panasiuk, et al.
Pageof 5